An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2012
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- 24 Mar 2012 Planned number of patients is 150 as reported by European Clinical Trials Database record.
- 21 May 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 21 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.